Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
cache
Home
cache
Next Post
Previous Post
cache
David Dornan, PhD
January 1, 2020
/
Uncategorized
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Read More
Stephen Rodin, JD
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in
TSC1
and
TSC2
using the Foundation Medicine genomic database
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
nab
-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
x
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
cache
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.